KLRK1 Human, Sf9
Killer Cell Lectin Like Receptor K1, Killer Cell Lectin-Like Receptor Subfamily K, Member 1, NKG2-D-Activating NK Receptor, NK Cell Receptor D, D12S2489E, NKG2D, DNA Segment On Chromosome 12 (Unique) 2489 Expressed Sequence, Killer Cell Lectin-Like Receptor Subfamily K Member 1, NKG2-D Type II Integral Membrane Protein, CD314 Antigen, NKG2-D, CD314, KLR.
Greater than 95.0% as determined by SDS-PAGE.
Description
KLRK1 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 386 amino acids (73-216a.a.) and having a molecular mass of 43.9kDa (Molecular size on SDS-PAGE will appear at approximately 40-57kDa).
KLRK1 is expressed with a 242 amino acids hIgG-His tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
Killer Cell Lectin Like Receptor K1, Killer Cell Lectin-Like Receptor Subfamily K, Member 1, NKG2-D-Activating NK Receptor, NK Cell Receptor D, D12S2489E, NKG2D, DNA Segment On Chromosome 12 (Unique) 2489 Expressed Sequence, Killer Cell Lectin-Like Receptor Subfamily K Member 1, NKG2-D Type II Integral Membrane Protein, CD314 Antigen, NKG2-D, CD314, KLR.
ADPIWSAVFL NSLFNQEVQI PLTESYCGPC PKNWICYKNN CYQFFDESKN WYESQASCMS QNASLLKVYS KEDQDLLKLV KSYHWMGLVH IPTNGSWQWE DGSILSPNLL TIIEMQKGDC ALYASSFKGY IENCSTPNTY ICMQRTVVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK HHHHHH.
Product Science Overview
The KLRK1 gene is located on chromosome 12p13.2 and encodes a type II transmembrane protein characterized by an extracellular C terminus and a C-type lectin domain . This protein is known for its ability to bind to a diverse family of ligands, including MHC class I chain-related proteins and UL-16 binding proteins .
KLRK1 is primarily expressed on NK cells, CD8-positive T cells, and some gamma/delta T cells . It functions as an activating receptor that triggers cytolytic responses against tumor cells and virus-infected cells . The interaction between KLRK1 and its ligands leads to the activation of NK and T cells, promoting the immune response against stressed cells .
The surface expression of KLRK1 ligands is crucial for the recognition of stressed cells by the immune system. This makes KLRK1 and its ligands potential therapeutic targets for the treatment of immune diseases and cancers . Research has shown that the activation of KLRK1 can enhance antitumor responses, making it a promising candidate for cancer immunotherapy .
